• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Delcath Systems Inc. (Amendment)

    2/13/24 5:00:11 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email
    SC 13G/A 1 ea193540-13ga1vivo_delcath.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

    Delcath Systems, Inc.

    (Name of Issuer)

     

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

     

    24661P807

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    þRule 13d-1(c)

     

    ☐Rule 13d-1(d)

      

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Fund Holdings, L.P.

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)   þ

     

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH REPORTING
    PERSON
    WITH
      5.   

    SOLE VOTING POWER

     

    2,708,579 (1)(2)

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    2,708,579 (1)(2)

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,708,579 (1)(2)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ¨

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.99% (2)

    12.  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The number represents (i) 1,666,746 shares of common stock, par value $0.01 per share (the “Common Stock”) of Delcath Systems, Inc. (the “Issuer”) and (ii) 1,041,833 shares of Common Stock issuable upon conversion of 6,251 shares of Series F-4 Convertible Preferred Stock, par value $0.01 per share (the “Series F-4 Preferred Stock”) underlying Tranche B warrants that are exercisable within 60 days of this Statement, based on 22,046,101 shares of Common Stock of the Issuer outstanding as of November 8, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 13, 2023. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)The Series F-4 Preferred Stock contains provisions preventing such Series F-4 Preferred Stock from being converted if such exercise would result in the holder obtaining greater than 9.99% of the Issuer’s voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series F-4 Preferred Stock in full, and do not give effect to the blocking provision.

      

    2

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)   ☐         (b)   þ

     

    3.  

    SEC USE ONLY

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH REPORTING
    PERSON
    WITH
      5.   

    SOLE VOTING POWER

     

    2,708,579 (1)(2)

      6.  

    SHARED VOTING POWER

     

    0

      7.  

    SOLE DISPOSITIVE POWER

     

    2,708,579 (1)(2)

      8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    _____2,708,579 (1)(2)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ¨

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.99% (2)

    12.  

    TYPE OF REPORTING PERSON

     

    OO

      

    (1)The number represents (i) 1,666,746 shares of Common Stock of the Issuer and (ii) 1,041,833 shares of Common Stock issuable upon conversion of 6,251 shares of Series F-4 Preferred Stock underlying Tranche B warrants that are exercisable within 60 days of this Statement, based on 22,046,101 shares of Common Stock of the Issuer outstanding as of November 8, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 13, 2023. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)The Series F-4 Preferred Stock contains provisions preventing such Series F-4 Preferred Stock from being converted if such exercise would result in the holder obtaining greater than 9.99% of the Issuer’s voting securities. However, the amounts reported in rows 5, 7 and 9 herein represent the number of shares of Common Stock that would be issuable upon conversion of the Series F-4 Preferred Stock in full, and do not give effect to the blocking provision.

      

    3

     

     

    Item 1.   Issuer
           
        (a) Name of Issuer:
           
        Delcath Systems, Inc. (the “Issuer”)
           
        (b) Address of Issuer’s Principal Executive Offices:
           
        1633 Broadway, Suite 22C,
    New York, New York 10019
           
    Item 2.   Filing Person
           
        (a) – (c) Name of Persons Filing; Address; Citizenship:
           
       

    (i)      Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and

     

    (ii)    Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is  the  general partner of Vivo Opportunity Fund Holdings, L.P.

     

    The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.

         
        (d) Title of Class of Securities:
           
        Common Stock, par value $0.01 per share (“Common Stock”).
           
        (e) CUSIP Number:  
         
        24661P807
           
    Item 3.    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
           
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
      (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
           
        If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                         

     

    4

     

     

    Item 4.    Ownership.        
         
        (a) and (b)   Amount beneficially owned:      
         
       

    The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.

     

    The shares reported in this Schedule 13G/A include 1,666,746 shares of Common Stock and 1,041,833 shares of Common Stock issuable upon conversion of 6,251 shares of Series F-4 Convertible Preferred Stock underlying Tranche B warrants that are exercisable within 60 days of this Statement. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    The Series F-4 Preferred Stock contains provisions preventing such Series F-4 Preferred Stock from being converted if such conversion would result in the holder obtaining greater than 9.99% of the Issuer’s voting securities. However, the amounts reported in this Item 4 represent the number of shares of Common Stock that would be issuable upon conversion of the Series F-4 Preferred Stock in full, and do not give effect to the blocking provision

         
        (c) Number of shares as to which such person has:

     

    Reporting Person  Sole Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Percentage of Common Stock Outstanding 
                         
    Vivo Opportunity Fund Holdings, L.P.   2,708,579       0    2,708,579        0    9.99%*
    Vivo Opportunity, LLC   2,708,579    0    2,708,579    0    9.99%*

     

    *The percent of class was based on 22,046,101 shares of Common Stock of the Issuer outstanding as of November 8, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 13, 2023, plus the shares of Common Stock underlying Series F-4 Preferred Stock held by Vivo Opportunity Fund Holdings, L.P., after giving effect to the blocking provision described above, which prevent the Reporting Persons from converting the Series F-4 Preferred Stock in excess of 9.99% of the Issuer’s voting securities.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    Not applicable.

       
    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.      

       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

       
    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable.      

       
    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable.      

       
    Item 10. 

    Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.      

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

    VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
       

    By: Vivo Opportunity, LLC

    Its: General Partner

     
       

    /s/ Kevin Dai

     

    Name: Kevin Dai

    Title: Managing Member

     

     
    VIVO OPPORTUNITY, LLC  
       

    /s/ Kevin Dai

     

    Name: Kevin Dai

    Title: Managing Member

     

     

     

    6

     

    Get the next $DCTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      1/23/24 4:36:46 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aharon Gil exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 1:00:03 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Salamon Steven A J exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:36:53 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Rosalind Advisors, Inc. exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:15:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025 at The Depot Renaissance Hotel in Minneapolis, MN. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PH

      5/15/25 4:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to eleven individuals whose employment commenced in March and April of 2025. The grants resulted in the right to purchase 111,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The options were granted on April 30, 2025, the date the Compensation Committee approved the stock option included within the equi

      5/9/25 5:30:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    SEC Filings

    See more

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DCTH
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 10-Q filed by Delcath Systems Inc.

      10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 9:25:44 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 7:42:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Delcath Systems Inc.

      DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      4/1/25 8:58:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Aharon Gil bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 3% to 1,069,710 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 8:00:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Salamon Steven A J bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 2% to 1,121,025 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 7:44:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Vukovic Vojo bought $120,000 worth of shares (40,000 units at $3.00), increasing direct ownership by 67% to 100,000 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      12/14/23 4:20:16 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

      SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 7:02:01 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

      NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

      3/18/24 5:20:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Delcath with a new price target

      Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

      6/28/24 8:18:39 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Delcath with a new price target

      Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:58:22 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity resumed coverage on Delcath with a new price target

      Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

      7/26/22 9:10:21 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Financials

    Live finance-specific insights

    See more
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Host First Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

      4/24/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively Gross mar

      3/6/25 8:00:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care